Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK2 | Q92630 | 6/20 | 0.69 |
| ▸ | CDK6 | Q00534 | 8/20 | 0.59 |
| ▸ | CCND1 | P24385 | 6/20 | 0.59 |
| ▸ | CDK4 | P11802 | 1/20 | 0.52 |
| ▸ | CCND3 | P30281 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 5/20 | 0.52 |
| ▸ | JAK3 | P52333 | 2/20 | 0.51 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.49 |
| ▸ | CDK9 | P50750 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4377094 | 0.90 | JAK2 (0.61) | DYRK2JAK2JAK3 | |
| SCHEMBL4378275 | 0.84 | JAK2 (0.61) | DYRK2JAK2JAK3 | |
| SCHEMBL31697637 | 0.81 | DYRK2 (1.00) | DYRK2CDK6CCND1 | |
| SCHEMBL8311018 | 0.80 | JAK2 (0.61) | DYRK2JAK2JAK3 | |
| SCHEMBL13911604 | 0.80 | JAK2 (0.59) | DYRK2CDK6CCND1JAK2JAK3 | |
| SCHEMBL4377671 | 0.79 | JAK2 (0.80) | JAK2JAK3 | |
| SCHEMBL4383183 | 0.78 | JAK2 (0.57) | JAK2JAK3 | |
| SCHEMBL4376909 | 0.78 | JAK2 (0.67) | DYRK2JAK2JAK3 | |
| SCHEMBL4376988 | 0.78 | JAK2 (0.68) | CDK6JAK2JAK3CDK9 | |
| SCHEMBL4384905 | 0.75 | JAK2 (0.70) | JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440663-B2 | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20090298830-A1 | 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298830-A1 | 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | DYRK2 72/4885CDK6 109/4885CCND1 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.